Liraglutide is a GLP-1 receptor agonist, and unlike most compounds discussed in the peptide market it carries full FDA approval backed by a substantial human clinical-trial record. It reaches patients as two separate branded products, Victoza for type 2 diabetes and Saxenda for chronic weight management, distinguished mainly by dose. It is prescription-only and administered as a once-daily subcutaneous injection under medical supervision.
Liraglutide is an FDA-approved GLP-1 receptor agonist marketed as Victoza for type 2 diabetes and as Saxenda at 3.0 mg for chronic weight management, lowering A1C by roughly 1.0 to 1.5 percentage points and producing average weight loss near 8 percent of body weight in clinical trials.
Liraglutide is a modified analog of human GLP-1, sharing about 97 percent of its structure, with a 16-carbon fatty-acid chain added so it binds reversibly to albumin and resists rapid breakdown. That single design change stretches the circulating half-life to roughly 13 hours, long enough for once-daily use. Because its insulin-releasing action is glucose-dependent, the molecule carries a low risk of hypoglycemia on its own, which separates it from insulin and sulfonylureas.
Liraglutide's 16-carbon fatty-acid chain lets it bind reversibly to albumin, extending its half-life to about 13 hours and enabling once-daily subcutaneous dosing.
Liraglutide holds two distinct FDA approvals that map to two brand names and two dose ranges. As Victoza it treats type 2 diabetes and, based on the LEADER outcomes trial, reduces the risk of major cardiovascular events in adults with established cardiovascular disease; as Saxenda at 3.0 mg it is approved for chronic weight management. The approved labeling for both excludes cosmetic weight loss in people at a healthy weight, a use that falls outside the evidence base and safety profile that supported approval.
| Criteria | Victoza | Saxenda |
|---|---|---|
| Indication | Type 2 diabetes | Chronic weight management |
| Approved | 2010 | 2014 |
| Maintenance dose | Up to 1.8 mg | 3.0 mg |
| Population | Adults, adolescents 10+ | BMI 30+, or 27+ with a comorbidity; adolescents 12-17 |
Liraglutide is approved as Victoza for type 2 diabetes at doses up to 1.8 mg and as Saxenda for chronic weight management at 3.0 mg, and Victoza also carries a cardiovascular risk-reduction indication from the LEADER trial.
The defining feature of liraglutide dosing is slow titration, a stepwise increase that exists to blunt the nausea a full starting dose would otherwise provoke. Published labeling describes a once-daily subcutaneous injection into the fat of the abdomen, thigh, or upper arm, taken without regard to meals as long as the timing stays roughly consistent. The two indications follow different schedules, with the weight-management target set higher and reached more gradually.
Liraglutide labeling describes a slow titration beginning at 0.6 mg daily and increasing by 0.6 mg weekly to a 3.0 mg maintenance dose for weight management, or to a maximum of 1.8 mg for type 2 diabetes.
The results reported for liraglutide depend on which outcome is measured and at what dose, and the human clinical evidence here is substantial rather than theoretical. Registration trials documented meaningful A1C reduction at the diabetes doses and roughly 8 percent average weight loss at the 3.0 mg dose in the SCALE program of trials. The published record is consistent that the benefit is tied to continued use, with much of the effect reversing after the drug is stopped.
In the SCALE program of trials liraglutide at 3.0 mg produced average weight loss of about 8 percent of starting body weight over roughly a year, with a majority of participants losing at least 5 percent.
The most common adverse effects reported for liraglutide are gastrointestinal, appearing during dose increases and usually easing as the body adapts. Beyond those, the drug carries a boxed warning, the strongest form of FDA prescribing caution, because rodents given liraglutide developed thyroid C-cell tumors, though whether that risk extends to humans remains unknown. The published safety record also documents associations with acute pancreatitis and gallbladder disease.
Liraglutide carries an FDA boxed warning for thyroid C-cell tumors observed in rodent studies and is absolutely contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN2.
Liraglutide was among the first GLP-1 receptor agonists in wide use, and newer agents in the class generally outperform it on convenience and, in several cases, on magnitude of effect. The most direct comparison is semaglutide, dosed once weekly and producing substantially greater weight loss in trials, while tirzepatide, a dual GLP-1/GIP agonist, reported larger results still. The record frames the choice as individual, weighing dosing frequency, tolerability, cost, and prescriber judgment rather than effect size alone.
| Criteria | Liraglutide | Semaglutide | Tirzepatide |
|---|---|---|---|
| Dosing | Once daily | Once weekly | Once weekly |
| Receptor target | GLP-1 | GLP-1 | GLP-1 and GIP |
| Reported weight loss | ~8% | ~15% at higher doses | Larger still in comparative trials |
| Brands | Victoza, Saxenda | Ozempic, Wegovy | Mounjaro, Zepbound |
Semaglutide is dosed once weekly and produced roughly 15 percent average weight loss at higher doses versus about 8 percent for once-daily liraglutide, while tirzepatide, a dual GLP-1/GIP agonist, reported larger results still.
Liraglutide is prescription-only in the United States, so legitimate access begins with an evaluation by a licensed clinician who confirms an appropriate indication. Branded list prices for both Victoza and Saxenda have run well over a thousand dollars a month without insurance, though few pay the full list price, and coverage for the weight-management indication is far more variable than for diabetes. The pricing picture is shifting as the original patents expire and lower-cost authorized generic versions enter the market.
Branded liraglutide has carried a list price above $1,000 per month, with weight-management coverage far more restricted than diabetes coverage, and authorized generic versions are now entering the market as the original patents expire.
The prescribing record draws a hard line between people for whom liraglutide is absolutely contraindicated and those who need careful evaluation first. The absolute bars trace directly to the boxed warning and to serious hypersensitivity. Several other conditions call for caution rather than exclusion, because gastrointestinal side effects can compound an existing problem.
Liraglutide is absolutely contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2, or a prior serious hypersensitivity reaction, and is generally avoided in pregnancy.
Liraglutide is designed as long-term maintenance therapy rather than a short course, because both its glucose-lowering and appetite-suppressing effects persist only while the drug is being taken. The multi-year LEADER trial gives it a reassuring cardiovascular record in high-risk type 2 diabetes, while discontinuation studies consistently show weight regain once treatment stops. Long-term monitoring focuses on the known concerns rather than new ones.
Liraglutide functions as long-term maintenance therapy whose benefits reverse after discontinuation, and the multi-year LEADER trial documented a reduction in major cardiovascular events in high-risk type 2 diabetes patients.
Educational use only. This article describes what the published scientific and clinical literature reports about Liraglutide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
